健康去哪儿
医院
健趣网登录 关闭
还没有账号？立即注册！
当前位置： 健趣网 www.patfun.com >  全球公益转诊 >  国际招募项目(中文)

The Late Presenter Treatment Optimisation Study

赞助:
合作者:
信息的提供 (责任方):
，
September 24, 2018
October 4, 2018
October 4, 2018
January 2019
January 2022   (主要结果测量的最终数据收集日期)
Time to treatment failure[ Time Frame: Earliest at 12 weeks, latest 48 weeks ]
Composite outcome: time to treatment failure due to either virological or clinical reasons. Virological reasons can either be insufficient virological response or viral rebound. Clinical reasons can be death related to HIV/AIDS/opportunistic infection or severe bacterial infection, new or recurrent AIDS defining event, any serious non-AIDS defining event or clinically relevant adverse events of any grade or immune reconstitution inflammatory syndrome requiring treatment
与当前相同
  • Proportion of patients with HIV-RNA viral load <50 copies/mL[ Time Frame: Week 24, 36 and 48 ]
  • HIV-1 drug resistance confirmed[ Time Frame: Through study completion, an average of 1 year ]
  • Time to reach CD4 count >200/µL[ Time Frame: Through study completion, an average of 1 year ]
  • CD4/CD8 ratio[ Time Frame: Week 4, 8, 12, 24, 36, 48 ]
  • Incidence of Immune Reconstitution Inflammatory Syndrome[ Time Frame: Week 48 ]
  • Incidence and duration of hospitalisation or rate of relapse of specific opportunistic or bacterial infection[ Time Frame: Week 48 ]
    Start/Stop of hospitalization for any reason Start/Stop of opportunistic infections as listed within Appendix 3 (AIDS defining events according to https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5710a2.htm) Start/Stop of severe BI, which consists of any of bacterial pneumonia, invasive bacterial infection (IBI) or any bacterial infectious disorder with grade 3 severity or requiring unscheduled hospital admission. An IBI is defined as the isolation of a bacterial organism from a normally sterile body site, or for bacterial nucleic acid to be detected at a normally sterile body site. Sterile body sites include blood, cerebrospinal fluid, pleural fluid, pericardial fluid, peritoneal fluid, joint fluid, bone aspirate, or a deep tissue abscess.
  • Number of participants with treatment-related adverse events as assessed by DAIDS AE Grading Table Corrected Version 2.1-July 2017[ Time Frame: Week 48 ]
  • Antiretroviral therapy and opportunistic or bacterial infection treatment changes and dose modifications due to toxicities and drug-drug interaction with antiretroviral therapy, and Immune Reconstitution Inflammatory Syndrome[ Time Frame: Week 48 ]
  • Health care resource use, including total inpatient days and emergency room visits[ Time Frame: Week 48 ]
  • Quality of life questionnaire outcomes[ Time Frame: Week 48 ]
    EQ-5D-3L questionnaires will be completed by patients throughout the study to assess any change throughout their treatment
  • Discontinuation or modification of study medication due to insufficient virological response or resistance mutation development[ Time Frame: Week 48 ]
    Discontinuation or modification of the single tablet regimen due virological reasons defined as a) Insufficient virological response, either: HIV-1 RNA reduction < 1 log 10 copies/mL at week 12, or Viral load > 50 HIV-1 RNA copies/mL at week 48 b) Viral rebound, which is subsequently confirmed at the following scheduled or unscheduled visit, defined as either: a. Rebound of HIV-1 RNA to >200 copies/mL after having achieved HIV-1 RNA <50 copies/mL b. Rebound of HIV RNA by >1 log 10 copies/mL from nadir value, for patients whose viral load has never been suppressed below 50 copies/mL
 
The Late Presenter Treatment Optimisation Study
An Open-Label, Multi-Centre, Randomised Study to Investigate Integrase Inhibitor Versus Boosted Protease Inhibitor Antiretroviral Therapy for Patients With Advanced HIV Disease

The main purpose of this study is to compare two different types of HIV treatments, in terms of effectiveness and improvement of side effects, for patients who are diagnosed with a more advanced HIV infection. Patients with advanced HIV infections are otherwise known as 'late presenters'. There are many effective treatments for HIV available; however, for late presenting patients the investigators do not know which type of treatment performs best. This is the first large study to compare treatments for patients in this situation, and the investigators hope that the results of this study will help doctors decide which treatments to use in the future. The two different types of treatment the investigators are comparing both contain a mixture of drugs that work together to combat HIV: The Boosted Protease Inhibitor combination (PI) which is a combination tablet containing: darunavir, cobicistat, emtricitabine and tenofovir alafenamide. It was approved for use in Europe under the brand name Symtuza®. The Integrase Inhibitor combination (INI). Which is a combination tablet containing: bictegravir, emtricitabine and tenofovir alafenamide. This is a a newer combination which was approved for use in Europe in June 2018 under the brand name of Biktarvy®. The main difference between the two treatments is how each one fights a HIV infection. They both stop a part of the virus from working (i.e. inhibit it), to prevent it from making copies of itself. The PI treatment contains drugs to stop the protease part of the virus, whereas the INI treatment contains drugs to stop the integrase part. In recent studies, it appears that treatments containing integrase inhibitors may be better for late presenting patients. They have been shown to quickly bring down the amount of virus in the body, and the side effects may be more acceptable to late presenters. To compare the two treatments, half of the participants on this study will be given the PI treatment, and the other half will be given the INI treatment.
The effectiveness of HIV antiretroviral therapy (ART) has consistently improved over the years. This is largely due to newer drugs having improved antiviral effectiveness and more tolerable side effect profiles; resulting in better viral suppression and improved treatment adherence. On the other hand, most recent clinical trials look at the effectiveness of ART in patients with less advanced disease. These patients usually suffer from less related diseases, drug-drug interactions, and other risks for treatment failure. Outside of these trials, the number of patients who present to clinic with a more developed advanced HIV infection, known as 'late presenters', remains high across Europe. Trials for these patients have tended to focus on the time of starting treatment and the management of infections. Much less is known about which ART treatments perform best for these late presenting patients; particularly in terms of virus suppression, immune system recovery, side effects and improvement of AIDs related diseases. No specific drug combinations have been compared in appropriate clinical trials before, and the international guidelines for first line treatment judge all therapies as equal standard of care for these patients. The investigators anticipate that Integrase inhibitor containing regimes may be better suited to patients with advanced disease, due to their beneficial side-effect profile and ability to rapidly decrease viral load levels. Therefore the investigators are conducting this clinical trial to compare an integrase inhibitor regime, against a protease inhibitor regime in patients with advanced HIV infection. The aim of the study is to demonstrate the non-inferiority of Biktarvy® against Symtuza®. Patients will be recruited from sites across Europe, and randomized onto either arm of the study. After randomisation onto either treatment regime, patients will attend approximately 9 follow-up visits over the course of a year. During these visits, patients will be asked to complete two questionnaires, to assess their quality of life and HIV symptoms. They will also be asked to provide a number of blood samples. These samples are to ensure that the patient is not resistant to the study drug and that their disease is not worsening. Samples to test for study drug resistance will be shipped to a laboratory for analysis in the even that the patient experiences virological failure. Biktarvy® will be supplied from Gilead and Symtuza® will be provided by Janssen Pharmaceuticals.
Interventional
Phase 3
分配: Randomized
干预模型: Single Group Assignment
干预模型描述:
盲法: Interventional
盲法描述:
主要目的: Treatment
  • Drug: Biktarvy
    Integrase inhibitor used to treat HIV-1 infection
  • Drug: Symtuza
    Protease inhibitor used to treat HIV-1 infection
  • Experimental: Biktarvy
    Bictegravir is an inhibitor of HIV-1 integrase that is being evaluated for the treatment of HIV-1 infection. Biktarvy® received marketing authorisation valid throughout the European Union (EU) in June 2018. Biktarvy is a combination of bictegravir, emtricitabine, and tenofovir (B/F/TAF). Method of administration: One combined B 50mg/F 200mg/TAF 25mg tablet taken orally once daily for up to 48 weeks without regard to food.
  • Experimental: Symtuza
    Symtuza® is a boosted PI indicated for the treatment of HIV-1 infection. Symtuza® received marketing authorisation valid throughout the EU in September 2017. Symtuza is a combination of darunavir, cobicistat, emtricitabine and tenofovir alafenamide (D/C/F/TAF) Method of administration: One combined D 800mg/C 150mg/F 200mg/TAF 10mg tablet taken orally once daily for up to 48 weeks with the addition of food.
 
Not yet recruiting
440
与当前相同
July 2022
January 2022   (主要结果测量的最终数据收集日期)
Inclusion Criteria: 1. The ability to understand and sign a written informed consent form (ICF) and must be willing to comply with all study requirements. 2. Male or non-pregnant, non-lactating females. 3. Age ≥ 18 years. 4. Has documented, untreated HIV-1 infection with either: 1. AIDS with any CD4 cell count (AIDS-defining conditions are listed within Appendix 3). Or 2. Severe bacterial infection (BI) and must have a CD4 cell count < 200/µl within 30 days prior to study entry. Or 3. Are asymptomatic with CD4 cell count < 100/µL within 30 days prior to study entry and must have an entry HIV viral load > 1000 copies/mL. Or 4. Currently receiving treatment for opportunistic infection (OI) i. Subjects with other serious OIs, including other AIDS-defining and AIDS-related OIs for which appropriate therapy other than ART exists are eligible, but Investigator approval must be obtained. ii. Current OI treatment must have been started ≤ 14 days prior to study entry, but can have been discontinued prior to study entry. 5. Have the ability to take oral medications. 6. If female and of childbearing potential, is using effective birth control methods (see Appendix 7) and is willing to continue practising these birth control methods during the trial and for at least 30 days after the last dose of study medication. Note: Non-childbearing potential is defined as either post-menopausal (12 months of spontaneous amenorrhoea and ≥45 years) or physically incapable of becoming pregnant with documented tubal ligation, hysterectomy or bilateral oophorectomy. 7. If a heterosexually active male, is using effective birth control methods and is willing to continue practising these birth control methods during the trial and for at least 30 days after the last dose of study medication. Exclusion Criteria: 1. Any antiretroviral prior to study entry. 2. Systemic cancer chemotherapy within 30 days prior to study entry, or current treatment for cancer (with the exception of Kaposi's sarcoma) or lymphoma. 3. Current or anticipated use of contraindicated medications (see Summary of Product Characteristics (SmPC) for Symtuza® and Investigator's Brochure (IB) for Biktarvy®) or anticipated systemic chemotherapy during study enrolment (administration of any contraindicated medication must be discontinued at least 30 days prior to the baseline visit and for the duration of the study). 4. Known resistance to the components of study medications (see section 6.1.3 for more details). 5. History or symptoms of advanced renal and/or hepatic impairment. Such as, kidney failure requiring dialysis; eGFR <30 mL/min; hepatic transaminases (AST and ALT) > 5 x upper limit of normal (ULN); or, platelet count <50,000. 6. Current drug or alcohol use that, in the opinion of the Investigator, would cause interference with the study. 7. Cryptococcal meningitis or active tuberculosis (TB) or current or expected treatment requiring Rifampicin or Rifabutin (patients with expected latent TB will have a TB test (IGRAs e.g. ELISPOT, QuantiFERON etc.) at their screening visit). 8. History or presence of allergy to the study drugs or their components, or drugs of their class. 9. Using any concomitant therapy disallowed as per the reference safety information (RSI) and product labelling for the study drugs. 10. Any investigational drug within 30 days prior to the study drug administration. 11. Patients with severe (Child Pugh class C) hepatic impairment. 12. Women who are pregnant, breastfeeding or plan to become pregnant or breastfeed during the study. 13. Females of childbearing potential and heterosexually active males must be willing to use a highly effective method of contraception. See Appendix 7 for further details. Such methods include: a. combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation: i. oral ii.intravaginal iii.transdermal b.progestogen-only hormonal contraception associated with inhibition of ovulation i.oral ii. injectable iii.implantable c. intrauterine device (IUD) d. intrauterine hormone-releasing system (IUS) e. bilateral tubal occlusion f. vasectomised partner g. sexual abstinence (with male partners)
参与研究的性别: All
最小年龄：18 Years ，最大年龄：N/A  
没有
Belgium|France|Germany|Ireland|Italy|Russian Federation|Spain|United Kingdom
 
Yes
研究美国FDA监管的药品: No
研究涉及美国FDA监管的设备产品: No
计划分享 IPD: Undecided
，
NEAT ID Foundation
Study Director: Georg Behrens Hannover Medical School
October 2018

ICMJE     国际医学期刊编辑委员会和 世界卫生组织 ICTRP 要求的元素
请使用微信扫码报名

关于健趣网     联系健趣网     获取帮助     服务条款     隐私政策     APP客户端     网站地图     手机版     临床路径

京ICP备11027633号-5 经营许可证编号：京B2-20192562 互联网药品信息服务资格证书2015-0088 京公网安备 11010102003638号
版权所有 © 2012-2020 健趣网